中国肺癌杂志2023，Vol.26Issue(12)：934-942,9.DOI:10.3779/j.issn.1009-3419.2023.106.26
免疫治疗在EGFR突变晚期非小细胞肺癌中的研究进展
Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer
刘尧尧 1苗健龙2
作者信息
- 1. 272000 济宁,济宁医学院临床医学院
- 2. 济宁市第一人民医院呼吸与危重症医学科
- 折叠
摘要
Abstract
Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)are currently the first-line standard of care for patients with non-small cell lung cancer(NSCLC)that harbor EGFR mutations.Nevertheless,resistance to EGFR-TKIs is inevitable.In recent years,although immune checkpoint inhibitors(ICIs)have significantly shifted the treatment paradigm in advanced NSCLC without driver mutation,clinical benefits of these agents are limited in patients with EGFR-mutated NSCLC.Compared with wild-type tumors,tumors with EGFR mutations show more heterogeneity in the expression level of programmed cell death ligand 1(PD-L1),tumor mutational burden(TMB),and other tumor microenvironment(TME)characteristics.Whether ICIs are suitable for NSCLC patients with EGFR mutations is still worth exploring.In this review,we summarized the clinical data with regard to the efficacy of ICIs in patients with EGFR-mutated NSCLC and deciphered the unique TME in EGFR-mutated NSCLC.关键词
肺肿瘤/表皮生长因子受体基因突变/免疫治疗Key words
Lung neoplasms/Epidermal growth factor receptor(EGFR)gene mutation/Immunotherapy引用本文复制引用
刘尧尧,苗健龙..免疫治疗在EGFR突变晚期非小细胞肺癌中的研究进展[J].中国肺癌杂志,2023,26(12):934-942,9.
